Top

Published in:

01-04-2020 | Breast Cancer | Original Article

Relative and Absolute Expression Analysis of MicroRNAs Associated with Luminal A Breast Cancer– A Comparison

Authors: Vahid Arabkari, Eoin Clancy, Róisín M. Dwyer, Michael J. Kerin, Olga Kalinina, Emma Holian, John Newell, Terry J. Smith

Published in: Pathology & Oncology Research | Issue 2/2020

Abstract

MicroRNAs, as small non-coding regulatory RNAs, play crucial roles in various aspects of breast cancer biology. They have prognostic and diagnostic value, which makes them very interesting molecules to investigate. Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) is the gold standard method to analyse miRNA expression in breast cancer patients. This study investigated two RT-qPCR methods (absolute and relative) to determine the expression of ten miRNAs in whole blood samples obtained from luminal A breast cancer patients compared to healthy controls. Whole blood samples were collected from 38 luminal A breast cancer patients and 20 healthy controls in Paxgene blood RNA tubes. Total RNA was extracted and analysed by relative and absolute RT-qPCR. For relative RT-qPCR, miR-16 was used as an endogenous control. For absolute RT-qPCR, standard curves were generated using synthetic miRNA oligonucleotides to determine the absolute copy number of each miRNA. Of the ten miRNAs that were analysed, the absolute RT-qPCR method identified six miRNAs (miR-16, miR-145, miR-155, miR-451a, miR-21 and miR-486) that were upregulated and one miRNA (miR-195) that was downregulated. ROC curve and AUC analysis of the data found that the combination of three miRNAs (miR-145, miR-195 and miR-486) had the best diagnostic value for luminal A breast cancer with an AUC of 0.875, with 76% sensitivity and 81% specificity. On the other hand, the relative RT-qPCR method identified two miRNAs (miR-155 and miR-486) that were upregulated and miR-195, which was downregulated. Using this approach, the combination of three miRNAs (miR-155, miR-195 and miR-486) was showed to have an AUC of 0.657 with 65% sensitivity and 69% specificity. We conclude that miR-16 is not a suitable normalizer for the relative expression profiling of miRNAs in luminal A breast cancer patients. Compared to relative quantification, absolute quantification assay is a better method to determine the expression level of circulating miRNAs in Luminal A breast cancer.

Available only for authorised users

WHO. World Health Organization (2015) Global health observatory data repository. 2015. Number of deaths (World) by cause. http://wwww.hoint/mediacentre/factsheets/fs310/en/

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer Journal international du cancer. 2015;136(5):E359–E386. https://doi.org/10.1002/ijc.29210 CrossRefPubMed

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403. https://doi.org/10.1016/j.ejca.2012.12.027 CrossRefPubMed

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature. 406(6797):747–752. https://doi.org/10.1038/35021093 CrossRefPubMed

Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR et al (2006) Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7:127. https://doi.org/10.1186/1471-2164-7-127 CrossRefPubMedPubMedCentral

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. https://doi.org/10.1093/annonc/mdr304 CrossRefPubMedPubMedCentral

Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678–5685. https://doi.org/10.1158/1078-0432.ccr-04-2421 CrossRefPubMed

Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39(5):673–677. https://doi.org/10.1038/ng2003 CrossRefPubMed

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature. 435(7043):834–838. https://doi.org/10.1038/nature03702 CrossRefPubMed

10.

Zen K, Zhang C-Y (2012) Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 32(2):326–348. https://doi.org/10.1002/med.20215 CrossRefPubMed

11.

Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16):7065–7070. https://doi.org/10.1158/0008-5472.CAN-05-1783 CrossRefPubMed

12.

Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ (2009, 2009) MicroRNAs as Novel Biomarkers for Breast Cancer. J Oncol:950201. https://doi.org/10.1155/2010/950201 CrossRef

13.

Tahiri A, Leivonen SK, Luders T, Steinfeld I, Ragle Aure M, Geisler J et al (2014) Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis. 35(1):76–85. https://doi.org/10.1093/carcin/bgt333 CrossRefPubMed

14.

McDermott AM, Miller N, Wall D, Martyn LM, Ball G, Sweeney KJ et al (2014) Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. PLoS One 9(1):e87032. https://doi.org/10.1371/journal.pone.0087032 CrossRefPubMedPubMedCentral

15.

Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA et al (2013) Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res 19(16):4477–4487. https://doi.org/10.1158/1078-0432.CCR-12-3401 CrossRefPubMed

16.

Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30(9):e36CrossRefPubMedPubMedCentral

17.

Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45CrossRefPubMedPubMedCentral

18.

Agarwal V, Bell GW, Nam JW, Bartel DP (2015) Predicting effective microRNA target sites in mammalian mRNAs. Elife 4. https://doi.org/10.7554/eLife.05005

19.

Klein D (2002) Quantification using real-time PCR technology: applications and limitations. Trends Mol Med 8(6):257–260CrossRefPubMed

20.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25(4):402–408. https://doi.org/10.1006/meth.2001.1262 CrossRefPubMed

21.

Mannhalter C, Koizar D, Mitterbauer G (2000) Evaluation of RNA isolation methods and reference genes for RT-PCR analyses of rare target RNA. Clin Chem Lab Med 38(2):171–177. https://doi.org/10.1515/cclm.2000.026 CrossRefPubMed

22.

Karge WH 3rd, Schaefer EJ, Ordovas JM (1998) Quantification of mRNA by polymerase chain reaction (PCR) using an internal standard and a nonradioactive detection method. Methods Mol Biol 110:43–61. https://doi.org/10.1385/1-59259-582-0:43 CrossRefPubMed

23.

Bustin SA (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25(2):169–193CrossRefPubMed

24.

Pfaffl MW, Hageleit M (2001) Validities of mRNA quantification using recombinant RNA and recombinant DNA external calibration curves in real-time RT-PCR. Biotechnol Lett 23(4):275–282. https://doi.org/10.1023/a:1005658330108 CrossRef

25.

Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, Vessella RL, Tewari M (2013) Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 10(10):1003–1005. https://doi.org/10.1038/nmeth.2633 CrossRefPubMedPubMedCentral

26.

Pohl G, Shih IM (2004) Principle and applications of digital PCR. Expert Rev Mol Diagn 4(1):41–47CrossRefPubMed

27.

Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Santiago I, Espino-Silva PK, Santuario-Facio SK, Ruiz-Flores P et al (2013) Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers 34(3):163–169CrossRefPubMedPubMedCentral

28.

Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, Ditzel HJ (2014) Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol 8(5):874–883. https://doi.org/10.1016/j.molonc.2014.03.002 CrossRefPubMedPubMedCentral

29.

Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES et al (2013) Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One 8(1):e53141. https://doi.org/10.1371/journal.pone.0053141 CrossRefPubMedPubMedCentral

30.

Rask L, Balslev E, Sokilde R, Hogdall E, Flyger H, Eriksen J et al (2014) Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. Cell Oncol (Dordr) 37(3):215–227. https://doi.org/10.1007/s13402-014-0176-6 CrossRef

31.

Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, Burda P, Pospisil V, Stopka T (2014) Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer 14:448. https://doi.org/10.1186/1471-2407-14-448 CrossRefPubMedPubMedCentral

32.

Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M et al (2012) Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res 18(21):5972–5982. https://doi.org/10.1158/1078-0432.ccr-12-1407 CrossRefPubMed

33.

Godfrey AC, Xu Z, Weinberg CR, Getts RC, Wade PA, LA DR et al (2013) Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res 15(3):R42. https://doi.org/10.1186/bcr3428 CrossRefPubMedPubMedCentral

34.

Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251(3):499–505. https://doi.org/10.1097/SLA.0b013e3181cc939f CrossRefPubMed

35.

Park IH, Kang JH, Lee KS, Nam S, Ro J, Kim JH (2014) Identification and clinical implications of circulating microRNAs for estrogen receptor-positive breast cancer. Tumour Biol 35:12173–12180. https://doi.org/10.1007/s13277-014-2525-5 CrossRefPubMed

36.

Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, Bayer CM, Bani MR, Richter S, Adamietz BR, Wenkel E, Rauh C, Beckmann MW, Fasching PA (2012) Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 7(1):e29770. https://doi.org/10.1371/journal.pone.0029770 CrossRefPubMedPubMedCentral

37.

Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ (2010) Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 15(7):673–682. https://doi.org/10.1634/theoncologist.2010-0103 CrossRefPubMedPubMedCentral

38.

Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, Chang G, Li X, Li Q, Wang S, Wang W (2014) MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One 9(5):e96228. https://doi.org/10.1371/journal.pone.0096228 CrossRefPubMedPubMedCentral

39.

Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J et al (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 58(10):1375–1381. https://doi.org/10.1136/gut.2008.167817 CrossRefPubMed

40.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci 105(30):10513–10518. https://doi.org/10.1073/pnas.0804549105 CrossRefPubMedPubMedCentral

41.

Liu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J (2013) Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin J Cancer Res 25(1):46–54. https://doi.org/10.3978/j.issn.1000-9604.2012.11.04 CrossRefPubMedPubMedCentral

42.

Calvano Filho CM, Calvano-Mendes DC, Carvalho KC, Maciel GA, Ricci MD, Torres AP et al (2014) Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p. Tumour Biol 35(8):7733–7741. https://doi.org/10.1007/s13277-014-2025-7 CrossRefPubMed

43.

Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG, Alvarez RH, Valero V, Hortobagyi GN, Calin GA, Ueno NT, Woodward WA, Reuben JM (2014) High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One 9(1):e83113. https://doi.org/10.1371/journal.pone.0083113 CrossRefPubMedPubMedCentral

44.

Mangolini A, Ferracin M, Zanzi MV, Saccenti E, Ebnaof SO, Poma VV, Sanz JM, Passaro A, Pedriali M, Frassoldati A, Querzoli P, Sabbioni S, Carcoforo P, Hollingsworth A, Negrini M (2015) Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. Biomarker Res 3:12. https://doi.org/10.1186/s40364-015-0037-0 CrossRef

45.

Zhang G, Liu Z, Cui G, Wang X, Yang Z (2014) MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells. Tumour Biol 35(11):11137–11145. https://doi.org/10.1007/s13277-014-2412-0 CrossRefPubMed

46.

Lerebours F, Cizeron-Clairac G, Susini A, Vacher S, Mouret-Fourme E, Belichard C, et al. miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness. Int J Cancer Journal international du cancer. 2013;133(7):1614–1623. https://doi.org/10.1002/ijc.28171 CrossRefPubMed

47.

O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, Paquette RL, Baltimore D (2008) Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205(3):585–594. https://doi.org/10.1084/jem.20072108 CrossRefPubMedPubMedCentral

48.

Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A (2005) BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 207(2):243–249. https://doi.org/10.1002/path.1825 CrossRefPubMed

49.

Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103(7):2257–2261CrossRefPubMedPubMedCentral

50.

Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C et al (2008) Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 3(7):e2557. https://doi.org/10.1371/journal.pone.0002557 CrossRefPubMedPubMedCentral

51.

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3):189–198. https://doi.org/10.1016/j.ccr.2006.01.025 CrossRefPubMed

52.

Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D et al (2016) MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 291(43):22855. https://doi.org/10.1074/jbc.A110.101055 CrossRefPubMedPubMedCentral

53.

Zhao FL, Dou YC, Wang XF, Han DC, Lv ZG, Ge SL et al (2014) Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer. Mol Biol Rep 41(9):5913–5922. https://doi.org/10.1007/s11033-014-3466-1 CrossRefPubMed

54.

Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y et al (2011) Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res 17(7):1722–1730. https://doi.org/10.1158/1078-0432.ccr-10-1800 CrossRefPubMed

55.

Luo Q, Wei C, Li X, Li J, Chen L, Huang Y et al (2014) MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer. Oncol Rep 31(3):1096–1102. https://doi.org/10.3892/or.2014.2971 CrossRefPubMedPubMedCentral

56.

Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao Y, Tang J, Chen X, Dai J, Wei Q, Zhang C, Shen H (2012) Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis. 33(4):828–834. https://doi.org/10.1093/carcin/bgs030 CrossRefPubMed

57.

Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P et al (2007) MicroRNA signatures in human ovarian cancer. Cancer Res 67(18):8699–8707. https://doi.org/10.1158/0008-5472.can-07-1936 CrossRefPubMed

58.

Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S et al (2008) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27(15):2128–2136. https://doi.org/10.1038/sj.onc.1210856 CrossRefPubMed

59.

Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65(14):6029–6033. https://doi.org/10.1158/0008-5472.can-05-0137 CrossRefPubMed

60.

Stuckrath I, Rack B, Janni W, Jager B, Pantel K, Schwarzenbach H (2015) Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients. Oncotarget. 6(15):13387–13401. https://doi.org/10.18632/oncotarget.3874 CrossRefPubMedPubMedCentral

61.

Shin VY, Siu JM, Cheuk I, Ng EK, Kwong A (2015) Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer 112(11):1751–1759. https://doi.org/10.1038/bjc.2015.143 CrossRefPubMedPubMedCentral

62.

Guo LJ, Zhang QY (2012) Decreased serum miR-181a is a potential new tool for breast cancer screening. Int J Mol Med 30(3):680–686. https://doi.org/10.3892/ijmm.2012.1021 CrossRefPubMed

63.

McDermott AM, Kerin MJ, Miller N (2013) Identification and validation of miRNAs as endogenous controls for RQ-PCR in blood specimens for breast cancer studies. PLoS One 8(12):e83718CrossRefPubMedPubMedCentral

64.

Lu J, Clark AG (2012) Impact of microRNA regulation on variation in human gene expression. Genome Res 22(7):1243–1254. https://doi.org/10.1101/gr.132514.111 CrossRefPubMedPubMedCentral

Title: Relative and Absolute Expression Analysis of MicroRNAs Associated with Luminal A Breast Cancer– A Comparison
Authors: Vahid Arabkari
Eoin Clancy
Róisín M. Dwyer
Michael J. Kerin
Olga Kalinina
Emma Holian
John Newell
Terry J. Smith
Publication date: 01-04-2020
Publisher: Springer Netherlands
Keywords: Breast Cancer
Breast Cancer
Published in: Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00627-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Bioinformatics Analysis Makes Revelation to Potential Properties on Regulation and Functions of Human Sox2

Solid-pseudopapillary Neoplasms of the Pancreas is still an Enigma: a Clinicopathological Review

C-X-C Chemokine Receptor Type 7 (CXCR-7) Expression in Invasive Ductal Carcinoma of Breast in Association with Clinicopathological Features

Spinal Versus Intracranial Meningioma: Aberrant Expression of CD10 and Inhibin with Relation to Clinicopathological Features and Prognosis

The Small Bowel Cancer Incidence Enigma

Attenuation of MAMLD1 Expression Suppresses the Growth and Migratory Properties of Gonadotroph Pituitary Adenomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer